U.S. Patent No. 1

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Retrieved on: 
Wednesday, November 29, 2023
Health, Medical Devices, Surgery, Health Technology, Other Health, Radiology, Biotechnology, U.S. Patent No. 1, Patent, NDRA, Pharmaceutical industry

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No.
  • 11730374, and is the second of two structural embodiments that ENDRA is patenting to further protect its core technology.
  • This 39th U.S. patent bolsters our thermoacoustic technology in areas of high unmet clinical need,” stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon.
  • “With a total of 71 patents granted worldwide, ENDRA possesses robust IP protection for its novel TAEUS’ technology in key global markets.”

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

Retrieved on: 
Friday, November 17, 2023
Sale, Exact Sciences (company), Colorectal cancer, Complaint, Intellectual property, Exact sciences, District court, Patent, Biomarker, Letter, U.S. Patent No. 1

MADISON, Wis., Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or offering for sale Geneoscopy's ColoSense product or otherwise infringing on Exact Sciences' U.S. Patent No. 11,634,781 ("the '781 Patent"). The filed complaint can be accessed on the Exact Sciences' website. 

Key Points: 
  • The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or offering for sale Geneoscopy's ColoSense product or otherwise infringing on Exact Sciences' U.S. Patent No.
  • Exact Sciences utilizes the patented '781 technology in its Cologuard® stool DNA-based colorectal cancer screening test.
  • After receiving a cease-and-desist letter from Exact Sciences regarding its patent infringement, Geneoscopy requested a reexamination of the '781 patent by the United States Patent and Trademark Office (USPTO) in May 2023.
  • Upon completion of the reexamination in October 2023, the USPTO rejected Geneoscopy's challenge, confirming the patentability of all claims of the '781 patent for Exact Sciences.

South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain

Retrieved on: 
Wednesday, November 1, 2023
Female, FDA, White Light Rock & Roll Review, Aes, Patent, Neuropathic pain, Wireless ambulatory ECG, U.S. Patent No. 1, Fast Track, Liver, MAD, Kidney, EPO, Volunteering, Priority review, Male, NSAIDS, Unified Patent Court, European Patent Office, PK, Accelerated approval (FDA), New Drug Application, Pain, Liver failure, Nonsteroidal anti-inflammatory drug, OBI Pharma, Inc., NDA, Fast track (FDA), Safety, Vital signs, Paracetamol, European Patent Convention, Plasma protein binding, Pharmaceutical industry, EU

NEW ORLEANS, Nov. 1, 2023 /PRNewswire/ -- South Rampart Pharma, Inc. ("South Rampart" or the "Company"), a clinical-stage life science company focused on developing innovative pain treatments, announced today the issuance of European Patent No. 3672938 by the European Patent Office (EPO) effective November 1, 2023. This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.

Key Points: 
  • This patent will apply to all Unified Patent Court-participating and non-participating European Unitary member states.
  • This patent, excluding possible patent term extensions, is expected to provide South Rampart with market exclusivity in the EPO member states until 2038, aligning with the U.S. Patent No.
  • On October 4, 2023, the U.S. FDA granted Fast Track designation to SRP-001 for acute pain.
  • The FDA Fast Track designation allows for more frequent interactions with the FDA, streamlining the clinical development plan and trial design to expedite drug approval.

Is AI the Future for the Evolution of Electronic Design Automation (EDA) Tools

Retrieved on: 
Tuesday, September 26, 2023
OTC Markets Group, Electronic design automation, Patent, Natural language processing, U.S. Patent No. 1, Epsilon, Todorov, Overheating, Integrated circuit, EDA, QOR, Deep learning, ChatGPT, IC, Optimality, Intelligence, Rittman, Ohio, Research, IP, SOC, DeepMind, NLP, Synopsis, Pulse, Electronic, Implementation, Electronic Design (magazine), Data analysis, GM, Machine learning, Algorithm, Engineering, Siemens Digital Industries Software, Artificial intelligence, Physics, GBT, Growth, Architecture, AI, Silicon, PPA, News, Dinu, Cadence Design Systems, Inc. v. Avanti Corp, Medical device, Printed circuit board, Cadence, Synopsys

According to allaboutcircuits.com ,"For years, EDA companies have claimed "artificial intelligence" features in their IC design tools.

Key Points: 
  • According to allaboutcircuits.com ,"For years, EDA companies have claimed "artificial intelligence" features in their IC design tools.
  • Over the last decade, there has been significant growth in the integration of AI technologies within Electronic Design Automation (EDA) tools.
  • AI has played a pivotal role in enhancing various aspects of EDA, such as design automation, optimization, verification, and physical design (Todorov & Dabral, 2020).
  • But it's no secret that electronic design automation (EDA) companies are folding AI into more of their offerings to speed up design and verification."

GBT Receives Patent Grant Notification Covering its Integrated Circuits Reliability Verification Analysis and Auto-Correction Technology

Retrieved on: 
Thursday, September 7, 2023
Patent, U.S. Patent No. 1, Epsilon, Overheating, EDA, IC, Research, Pulse, Data analysis, Machine learning, SAN, Algorithm, OTC, Physics, GBT, Printed circuit board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. (OTC PINK: GTCH) ("GBT” or the “Company”), received a grant notification for its microchip’s reliability verification and auto-correction EDA patent application, internal project’s code name, Epsilon. The patent will be granted as U.S. Patent No. 11,763,062 on September 19, 2023. GBT’s Epsilon patent application covers the innovative technology to address advanced semiconductor node physics with the goal of ensuring a high level of reliability, optimal thermal design, lower power consumption and high performance. The described technology includes machine learning algorithms to enable robust design, process optimization, characterization, modeling, and simulation. The technology underlying the patent identifies reliability flaws, describes the found issues, and allows an automatic correction of these reliability issues early during the IC’s design phase. Machine Learning techniques will be performing data analysis, identification, categorization, and reasoning about executing the optimal IC layout automatic correction. The technology aims to allow IC designers to analyze and fix circuits early during the design phase in real time with the goal of creating higher efficiencies. GBT plans to continue its R&D efforts in this domain, inventing modern technologies and enabling reliable, low-power, high-performance, next-generation microchips.

Key Points: 
  • The Patent is scheduled for Grant on September 19, 2023
    SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- GBT Technologies Inc. ( OTC PINK: GTCH ) ("GBT” or the “Company”), received a grant notification for its microchip’s reliability verification and auto-correction EDA patent application, internal project’s code name, Epsilon.
  • The described technology includes machine learning algorithms to enable robust design, process optimization, characterization, modeling, and simulation.
  • The technology underlying the patent identifies reliability flaws, describes the found issues, and allows an automatic correction of these reliability issues early during the IC’s design phase.
  • Our Epsilon patent is an intelligent design productivity enhancement EDA software solution that analyzes, detects, and eliminates electrical reliability issues on-the-fly.

Shoals Technologies Group Files Motion to Amend Patent Infringement Complaint with ITC, Adding Additional Claims Against Voltage with New Technology Patent

Retrieved on: 
Thursday, July 27, 2023
U.S. Patent No. 1, Patent, EV, United States International Trade Commission, United States Patent and Trademark Office, Tariff Act, Voltage, Complaint, Shoal, Motion, District court, Engineering, ITC, BLA, Generic drug, Printed circuit board

On June 27, 2023, the United States Patent and Trademark Office issued U.S. Patent No.

Key Points: 
  • On June 27, 2023, the United States Patent and Trademark Office issued U.S. Patent No.
  • 11,689,153 B2 (the “’153 patent”), owned by Shoals and relating to improved connectors for solar panel arrays.
  • Upon issuance of the ‘153 patent’ Shoals filed a motion to amend its patent infringement complaint with the ITC, adding additional claims against Voltage.
  • As previously announced , the U.S. ITC has instituted an investigation into allegations of patent infringement against Hikam America, Inc. and Voltage, LLC.

ITC Accepts Shoals Technologies Group’s Complaint to Investigate Alleged Importation of Infringing Hikam and Voltage Products

Retrieved on: 
Tuesday, June 20, 2023
Patent, Interim, U.S. Patent No. 1, EV, United States International Trade Commission, Tariff Act, Voltage, Engineering, ITC, BLA, Shoal

The ITC’s decision is based on the previously announced complaint filed by Shoals requesting that the ITC bar the importation of the alleged infringing products into the United States under Section 337 of the Tariff Act of 1930.

Key Points: 
  • The ITC’s decision is based on the previously announced complaint filed by Shoals requesting that the ITC bar the importation of the alleged infringing products into the United States under Section 337 of the Tariff Act of 1930.
  • As a result of the decision, the ITC will investigate the unlawful imports of certain photovoltaic connectors and components that infringe two valid and enforceable patents owned by Shoals relating to improved connectors for solar panel arrays (U.S. Patent No.
  • Shoals’ complaint requests that the ITC issue a limited exclusion order and a cease and desist order against Hikam, Voltage and related entities to bar the importation into the United States of devices, components and products that are alleged to infringe Shoals’ patents.
  • The patented connectors are less expensive to manufacture and transport than alternatives, easy to use, and permit a more simplified component configuration in the solar field.

Shoals Technologies Group Files Patent Infringement Complaint with ITC Against Hikam and Voltage

Retrieved on: 
Thursday, May 4, 2023
Patent, Interim, U.S. Patent No. 1, EV, United States International Trade Commission, Tariff Act, History, Voltage, Complaint, District court, Engineering, ITC, BLA, Safety, Renewable energy, Ghurar al-Hikam wa Durar al-Kalim, Shoal

PORTLAND, Tenn., May 04, 2023 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of systems (“EBOS”) solutions for solar, storage, and electric vehicle (EV) charging infrastructure, announced today that it has filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hikam America, Inc., based in Chula Vista, California (“Hikam”), and Voltage, LLC, based in Chapel Hill, North Carolina (“Voltage”).

Key Points: 
  • PORTLAND, Tenn., May 04, 2023 (GLOBE NEWSWIRE) -- Shoals Technologies Group, Inc. (“Shoals” or the “Company”) (Nasdaq: SHLS), a leading provider of electrical balance of systems (“EBOS”) solutions for solar, storage, and electric vehicle (EV) charging infrastructure, announced today that it has filed a patent infringement complaint with the U.S. International Trade Commission (ITC) against Hikam America, Inc., based in Chula Vista, California (“Hikam”), and Voltage, LLC, based in Chapel Hill, North Carolina (“Voltage”).
  • The complaint also names related foreign entities of both Hikam and Voltage.
  • Shoals is requesting that the ITC institute an investigation into the alleged infringement under Section 337 of the Tariff Act of 1930 to bar the importation of the alleged infringing products into the United States.
  • Shoals’ complaint requests that the ITC issue a limited exclusion order and a cease and desist order against Hikam, Voltage and related entities to bar the importation into the United States of devices, components and products that are alleged to infringe Shoals’ patents.

OTORIO Secures U.S. Patent for Innovative Operational Network Risk Mitigation System and Method

Retrieved on: 
Tuesday, May 2, 2023
OT, U.S. Patent No. 1, NIST, Patent, Risk management, Organization, TEL, Risk

The USPTO issued U.S. Patent No. 11637853, "Operational Network Risk Mitigation System and Method," for OTORIO's algorithm simulation model, which underpins its end-to-end OT cybersecurity platform. The company's unique technology calculates OT cybersecurity threats by analyzing and visualizing four key components -- threat, likelihood, vulnerability, and impact -- and provides risk mitigation actions prioritized according to actual exposure and potential impact on operations. This enables organizations to take proactive measures to safeguard their critical assets and processes.

Key Points: 
  • This marks a significant milestone for OTORIO's proprietary technology and further validates the company as a pioneer in the OT security market.
  • 11637853 , "Operational Network Risk Mitigation System and Method," for OTORIO's algorithm simulation model, which underpins its end-to-end OT cybersecurity platform.
  • This provides crucial context to OT cybersecurity posture, along with concise calls to action, enabling organizations to prioritize and address risk effectively.
  • "This patent recognizes our innovative approach to quantifying OT cyber risk and positions us as market leaders," said Yair Attar, co-founder & CTO, OTORIO.

PaymentVision® Wins Landmark Patent Directed Toward Integrated, Secure Tokenized Payments

Retrieved on: 
Thursday, April 27, 2023
U.S. Patent No. 1, Patent, IVR, City centre, API, Fintech, ACH, PCI, Organization, Corporation, Pharmaceutical industry, Online shopping

JACKSONVILLE, Fla., April 27, 2023 /PRNewswire/ -- This newly-issued patent builds upon Autoscribe's most recent patents, U.S. Patent No. 9,576,279 and U.S. Patent No. 10,423,940, which cover, at a high level, particular technical steps of facilitating secure payments within a client computing system, without exposing financial information, thereby significantly reducing or eliminating the PCI compliance burden of an integrated client or core system.

Key Points: 
  • Autoscribe Corporation d/b/a PaymentVision, a leading Fintech and payment processor, announces the issuance of its newest patent, U.S. Patent No.
  • JACKSONVILLE, Fla., April 27, 2023 /PRNewswire/ -- This newly-issued patent builds upon Autoscribe's most recent patents, U.S. Patent No.
  • 10,423,940 , which cover, at a high level, particular technical steps of facilitating secure payments within a client computing system, without exposing financial information, thereby significantly reducing or eliminating the PCI compliance burden of an integrated client or core system.
  • Autoscribe CEO Robert Pollin stated, "We are thrilled to have this innovation recognized by the U.S. Patent and Trademark Office.